# Naurex

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/naurex

- Industry: Biotechnology
- Headquarters: Evanston, US
- Website: www.naurex.com
- Total disclosed funding: $129M
- Latest round: Series C (Dec 2, 2014)
- Investors on record: 18

## About

Naurex Inc. is a biopharmaceutical company focused on developing innovative therapies for psychiatric and neurological disorders, leveraging advanced drug discovery technologies to enhance patient care.Naurex Inc. specializes in creating novel therapies for mental health conditions. Founded by Derek Small, the company has its headquarters in Evanston, US. In December 2014, Naurex raised USD 80 mn in Series C funding. This investment round attracted various notable investors, including Cowen Inc., EcoR1 Capital, and Takeda Ventures, along with other undisclosed entities. Over its journey, Naurex has engaged in six deals, with the most recent deal completed in December 2014.Naurex Inc. focuses on the development of innovative treatments for psychiatric and neurological disorders. Their leading product candidates aim to address unmet medical needs in areas such as depression, anxiety, and cognitive dysfunction. The company's research emphasizes targeting underlying biological mechanisms to improve patient outcomes, thereby enhancing the standard of care for individuals affected by these conditions.Naurex generates revenue through strategic partnerships and collaborations with healthcare organizations, focusing on the biopharmaceutical sector. Their revenue model includes product sales directed towards healthcare providers and specialty pharmacies, with an emphasis on addressing both adult and pediatric patient populations. The company benefits from alignment with various stakeholders, which supports its market presence and financial performance.Naurex Inc. plans to leverage the recent USD 80 mn from their Series C funding to support the development of new therapeutic products aimed at treating psychiatric disorders. The company aims to expand its market reach into Europe and Asia by 2025, capitalizing on strategic partnerships to facilitate entry into these regions. As they continue to innovate, Naurex is positioned to release additional product candidates in the coming years, focusing on enhancing treatment options for patients.

## Funding rounds

- Series C, Dec 2, 2014, $80M — Adams Street Partners, Latterell Venture Partners, Genesys Capital Management, Lundbeck Inc., Savitr Capital LLC, Druid BioVentures, PathoCapital, Takeda Ventures, Baxter Ventures, Northwestern University, Cowen Inc., EcoR1 Capital, Sabby Capital, Portola Capital Partners, Goudy Park Capital
- Series B, Dec 17, 2012, $38M — Adams Street Partners, Latterell Venture Partners, Genesys Capital Management, Shire, Lundbeck Inc., Savitr Capital LLC, Druid BioVentures, PathoCapital, Takeda Ventures, Baxter Ventures, Northwestern University
- Series A, May 11, 2011, $11M — Adams Street Partners, Latterell Venture Partners, Genesys Capital Management, Shire, Lundbeckfond Ventures, Druid BioVentures, PathoCapital, Takeda Pharmaceutical

## Investors

- Adams Street Partners (https://capitalatlas.ai/funds/adams-street-partners) — Series A, Series B, Series C
- Latterell Venture Partners (https://capitalatlas.ai/funds/latterell-venture-partners) — Series A, Series B, Series C
- Genesys Capital Management (https://capitalatlas.ai/funds/genesys-capital-management) — Series A, Series B, Series C
- Shire — Series A, Series B
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series A
- Druid BioVentures — Series A, Series B, Series C
- PathoCapital (https://capitalatlas.ai/funds/pathocapital) — Series A, Series B, Series C
- Takeda Pharmaceutical — Series A
- Lundbeck Inc. — Series B, Series C
- Savitr Capital LLC — Series B, Series C
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series B, Series C
- Baxter Ventures (https://capitalatlas.ai/funds/baxter-ventures) — Series B, Series C
- Northwestern University — Series B, Series C
- Cowen Inc. — Series C
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series C
- Sabby Capital (https://capitalatlas.ai/funds/sabby-capital) — Series C
- Portola Capital Partners — Series C
- Goudy Park Capital — Series C